Physician profile

Jeffrey Travis

Thoracic Surgery (Cardiothoracic Vascular Surgery) · West Columbia, SC

NPI 1174571533

$5,277.84

in general payments reported to CMS, 2019-2025

41 companies · $1,518 in 2025

The $1,518 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,941.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Atricure, INC. $2,110.26 2019-2025 Atriclip Laa Exclusion System, Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax
W. L. Gore & Associates, INC. $551.02 2020
Edwards Lifesciences Corporation $405.63 2019-2025 Mitris Resilia Mitral Valve, Konect Resilia
Abiomed $379.65 2023-2025 Impella
Angiodynamics, INC. $196.33 2020-2025 Angiovac
Intuitive Surgical, INC. $181.80 2019-2025
Baxter Healthcare $158.36 2019-2025 Preveleak
Clearflow INC. $134.57 2019
Lemaitre Vascular, INC. $120.60 2022-2023 Artegraft Vascular Graft
Medtronic, INC. $82.63 2021-2025 Ligasure, Corevalve Evolut R, Avalus
Boston Scientific Corporation $74.22 2019-2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $71.85 2019-2023 Lifevest
Abbott Laboratories $57.06 2023 Navitor
Alnylam Pharmaceuticals INC. $48.47 2024 Onpattro
E.R. Squibb & Sons, L.L.C. $43.77 2019-2022
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Artivion, INC. $42.71 2023-2024 Bioglue Surgical Adhesive, On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder, Cardiac Non-Synergraft
Peerless Surgical INC. $42.18 2024
La Jolla Pharmaceutical Company $39.22 2022-2025 Giapreza
Ethicon US, LLC $39.00 2022-2024 Surgicel Nu-Knit, Dermabond Prineo, Vistaseal
Conmed Corporation $38.46 2019
Becton, Dickinson and Company $38.46 2019
On Target Laboratories, INC $37.70 2025 Cytalux
Kci USA, INC. $32.65 2019-2022
Bolton Medical INC $32.32 2022
Amgen INC. $31.53 2019
Mallinckrodt Enterprises LLC $28.93 2019
Getinge USA Sales, LLC $27.70 2024 Cardiohelp
Medtronic Vascular, INC. $26.03 2019-2020
Integra Lifesciences Corporation $25.59 2020
Bard Access Systems, INC. $22.07 2019
Terumo Cardiovascular Systems Corporation $19.44 2019
Portola Pharmaceuticals, LLC $18.96 2019
Livanova USA, INC. $16.67 2019
Ambu INC. $15.84 2025
Chiesi USA, INC. $15.55 2019
Biom'Up France Sas $13.10 2020
Janssen Pharmaceuticals, INC $12.44 2019
Zimmer Biomet Holdings, INC. $12.30 2019
Grifols USA, LLC $12.04 2019
Molnlycke Health Care US, LLC $10.73 2020
Biomerieux INC $10.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jeffrey Travis

$5,277.84

in general payments reported 2019-2025

Years
2019-2025
Top company
Atricure, INC.
Context
The $1,518 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).

https://glasscript.com/doctor/98929/jeffrey-travis

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.